Clinical Trial Results:
A randomised control trial to determine whether a 5 day course of antibiotics is more clinically and cost effective than a 24 hour prophylactic course for the prevention of surgical site infection following lower limb amputation surgery
Summary
|
|
EudraCT number |
2012-003146-32 |
Trial protocol |
GB |
Global end of trial date |
28 Dec 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Oct 2020
|
First version publication date |
07 Oct 2020
|
Other versions |
|
Summary report(s) |
ASSIT main results and summary report ASSIT Choice of Statistical Tests |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ASSIT
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Hull University Teaching Hospital NHS Trust
|
||
Sponsor organisation address |
Anlaby Road, Hull, United Kingdom, HU3 2JZ
|
||
Public contact |
Judith Long, Academic Vascular Surgical Unit, Hull Royal Infirmary, 01482 675784, judith.long@hey.nhs.uk
|
||
Scientific contact |
Panos Souroullas, Academic Vascular Surgical Unit, Hull Royal Infirmary, 01482 675784, sourou@doctors.org.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Jan 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
12 Jan 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Dec 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Primary objective: to establish if a 5 day course of antibiotics is more clinically and cost effective than a 24 hour prophylactic course in preventing surgical site infection in patients undergoing lower limb amputation.
|
||
Protection of trial subjects |
Full written informed consent was received from all participants prior to any study procedures. Patients were free to withdraw from the study at any time.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jan 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 161
|
||
Worldwide total number of subjects |
161
|
||
EEA total number of subjects |
161
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
73
|
||
From 65 to 84 years |
77
|
||
85 years and over |
11
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
A total of 208 patients were screened for eligibility of which 161 patients were recruited and randomised between 17th October 2013 and 12th December 2015. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
All patients undergoing either transfemoral, transtibial or transmetatasal amputation were screened: Inclusion Adults ≥18 yrs undergoing MLLA. Exclusion Allergies to chlorhexidine/alcohol/ iodophors Admitted to hospital requiring emergency amputation due to severe sepsis Use of investigational drug/device therapy within preceding 4 weeks | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Baseline (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Single blind | |||||||||||||||
Roles blinded |
Assessor [1] | |||||||||||||||
Blinding implementation details |
Blinding of treating surgical team and participant was not performed. Blinding of the investigator assessing outcomes was achieved by having outcome assessments performed by a member of the research team who was unaware of treatment allocation.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
5-day Antibiotic Group | |||||||||||||||
Arm description |
Both treatment groups received 24 hours of intravenous (IV) treatment, consisting of three doses of 1.2g of amoxicillin with clavulanic acid and 500mg of metronidazole eight hours apart starting on induction of anaesthesia. In cases of amputations proximal to the transtibial level, a single weight-adjusted dose of gentamicin (7mg/Kg) was also administered on induction. Those in the five-day treatment arm received further oral antibiotic prophylaxis with 625mg of Co-amoxiclav TDS and 400mg metronidazole administered three times a day for four days. | |||||||||||||||
Arm type |
Active comparator | |||||||||||||||
Investigational medicinal product name |
Co-amoxiclav
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Augmentin
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
|
|||||||||||||||
Investigational medicinal product name |
Metronidazole
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Flagyl
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
|
|||||||||||||||
Investigational medicinal product name |
Iodine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Povidone iodine
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous solution
|
|||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||
Dosage and administration details |
Intra-operative skin preparation prior to incision to skin.
|
|||||||||||||||
Investigational medicinal product name |
Chlorhexidine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Hydrex
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous solution
|
|||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||
Dosage and administration details |
Alcoholic Chlorhexidine skin pre-op preparation
|
|||||||||||||||
Investigational medicinal product name |
Teicoplanin
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Powder and solution for solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
|
|||||||||||||||
Investigational medicinal product name |
Clindamycin
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
|
|||||||||||||||
Arm title
|
24 Hour Antibiotic Group | |||||||||||||||
Arm description |
Both treatment groups received 24 hours of intravenous (IV) treatment, consisting of three doses of 1.2g of amoxicillin with clavulanic acid and 500mg of metronidazole eight hours apart starting on induction of anaesthesia. In cases of amputations proximal to the transtibial level, a single weight-adjusted dose of gentamicin (7mg/Kg) was also administered on induction. Participants in the 24-hour treatment arm received no further antibiotics | |||||||||||||||
Arm type |
Active comparator | |||||||||||||||
Investigational medicinal product name |
Co-amoxiclav
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Augmentin
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
|
|||||||||||||||
Investigational medicinal product name |
Iodine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Povidone iodine
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous solution
|
|||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||
Dosage and administration details |
Intra-operative skin preparation prior to incision to skin.
|
|||||||||||||||
Investigational medicinal product name |
Metronidazole
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Flagyl
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
|
|||||||||||||||
Investigational medicinal product name |
Chlorhexidine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Hydrex
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous solution
|
|||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||
Dosage and administration details |
Alcoholic Chlorhexidine skin pre-op preparation
|
|||||||||||||||
Investigational medicinal product name |
Teicoplanin
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Powder and solution for solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
|
|||||||||||||||
Notes [1] - The roles blinded appear inconsistent with a simple blinded trial. Justification: Blinding of treating surgical team and participant was not performed. Blinding of the investigator assessing outcomes was achieved by having outcome assessments performed by a member of the research team who was unaware of treatment allocation. |
||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
5-day Antibiotic Group
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Both treatment groups received 24 hours of intravenous (IV) treatment, consisting of three doses of 1.2g of amoxicillin with clavulanic acid and 500mg of metronidazole eight hours apart starting on induction of anaesthesia. In cases of amputations proximal to the transtibial level, a single weight-adjusted dose of gentamicin (7mg/Kg) was also administered on induction. Those in the five-day treatment arm received further oral antibiotic prophylaxis with 625mg of Co-amoxiclav TDS and 400mg metronidazole administered three times a day for four days. | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
24 Hour Antibiotic Group
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Both treatment groups received 24 hours of intravenous (IV) treatment, consisting of three doses of 1.2g of amoxicillin with clavulanic acid and 500mg of metronidazole eight hours apart starting on induction of anaesthesia. In cases of amputations proximal to the transtibial level, a single weight-adjusted dose of gentamicin (7mg/Kg) was also administered on induction. Participants in the 24-hour treatment arm received no further antibiotics | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
5-day Antibiotic Group
|
||
Reporting group description |
Both treatment groups received 24 hours of intravenous (IV) treatment, consisting of three doses of 1.2g of amoxicillin with clavulanic acid and 500mg of metronidazole eight hours apart starting on induction of anaesthesia. In cases of amputations proximal to the transtibial level, a single weight-adjusted dose of gentamicin (7mg/Kg) was also administered on induction. Those in the five-day treatment arm received further oral antibiotic prophylaxis with 625mg of Co-amoxiclav TDS and 400mg metronidazole administered three times a day for four days. | ||
Reporting group title |
24 Hour Antibiotic Group
|
||
Reporting group description |
Both treatment groups received 24 hours of intravenous (IV) treatment, consisting of three doses of 1.2g of amoxicillin with clavulanic acid and 500mg of metronidazole eight hours apart starting on induction of anaesthesia. In cases of amputations proximal to the transtibial level, a single weight-adjusted dose of gentamicin (7mg/Kg) was also administered on induction. Participants in the 24-hour treatment arm received no further antibiotics |
|
|||||||||||||
End point title |
Incidence of Surgical Site Infection | ||||||||||||
End point description |
Incidence of SSI within 30 days of the procedure using the ASEPSIS score as an objective measure of wound healing. Occurrence of a SSI was defined as positive finding at any of the three follow-ups with an ASEPSIS score of ≥ 21.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
30 days
|
||||||||||||
|
|||||||||||||
Attachments |
ASSIT Choice of Statistical Tests |
||||||||||||
Statistical analysis title |
Logistic regression analysis | ||||||||||||
Statistical analysis description |
Continuous data: If the data appeared normally distributed the Kolmogorov statistic or Shapiro Wilk statistic was utilized to confirm this, with a P value > 0.05 indicating normality. P values are quoted to 3 decimal places with values of less than 0.05 being considered significant
Categorical data: The primary test utilized was Pearson’s Chi squared test. If more than 20% of the expected frequencies were <5 or if any were <1 then the Fisher’s exact test was utilized.
|
||||||||||||
Comparison groups |
5-day Antibiotic Group v 24 Hour Antibiotic Group
|
||||||||||||
Number of subjects included in analysis |
152
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [1] | ||||||||||||
P-value |
< 0.05 [2] | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|||||||||||||
Notes [1] - SPSS - see uploaded results for full analysis [2] - The use of a 5-day antibiotic course was found to be associated with statistically significant 27.7% absolute risk reduction in the incidence of SSI (P=0.000096-Pearson’s χ2 test) |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
Adverse events will be reported in accordance with the Trust's R&D department’s Safety Reporting standard operating procedure (R&D GCP SOP 07) to ensure compliance with UK Clinical Trial Regulations.
|
||
Adverse event reporting additional description |
The AE reporting period for this trial begins as soon as patients have consented to the trial and ends 30 days after patient’s operation date, which signifies the endpoint for the primary objective of this clinical trial.
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
17.0
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: See plot 7 in study main results and findings file to see percentage of complications amongst all groups. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
02 Aug 2013 |
Change of antibiotics for patients with penicillin allergies. |
||
12 Feb 2014 |
Patient sample size changed from 164 to 168 and SAE reporting requirements clarified |
||
26 Jun 2014 |
To add third pre-op skin preparation alcoholic povidone iodine |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |